Can-Fite BioPharma

Company Overview

Snapshot

Founded in September 1994 by Ilan Cohn, Can-Fite BioPharma operates with 11–50 employees. The company has raised a total of $117.45 million across 21 funding rounds from 2 investors. In July 2025, Can-Fite BioPharma went public on the NYSE.

Business overview

Can-Fite BioPharma is an Israeli biopharmaceutical company focused on discovering and developing proprietary drug candidates for inflammatory, liver, and metabolic diseases, as well as cancer. Its platform technology targets the Gi protein-associated A3 adenosine receptor (A3AR), which is highly expressed in pathological cells. The company's compounds, including Piclidenoson (CF101), Namodenoson (CF102), and CF602, are designed to modulate NF-kB and Wnt signal transduction pathways to achieve anti-inflammatory and anticancer effects. Can-Fite operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development, serving global markets.

Strategic signal

Can-Fite BioPharma is actively advancing its oncology pipeline, as evidenced by the FDA granting Orphan Drug Designation to its Namodenoson for pancreatic cancer in October 2024. This designation highlights the drug's potential to address a significant unmet medical need and provides regulatory incentives, signaling a strong focus on developing treatments for challenging diseases and potentially accelerating market access.

Company Intelligence Q&A

What was a significant regulatory milestone for Can-Fite BioPharma's Namodenoson?

In October 2024, the FDA granted Orphan Drug Designation to Can-Fite BioPharma’s Namodenoson for the treatment of pancreatic cancer. This designation supports the development of drugs for rare diseases.

What recent patent was secured by Can-Fite BioPharma?

In November 2024, Can-Fite BioPharma secured an Australian patent for its anti-obesity drug, Namodenoson, indicating progress in expanding intellectual property protection for its pipeline.

What was a key development regarding Can-Fite BioPharma's pancreatic carcinoma study?

In September 2024, Can-Fite BioPharma's Phase IIa clinical study with Namodenoson for pancreatic carcinoma received regulatory authorization from the Israeli Ministry of Health, allowing the trial to proceed.

What was a recent commercial development for Can-Fite BioPharma's Piclidenoson?

In September 2024, Vetbiolix exercised its option and licensed Piclidenoson for veterinary osteoarthritis, projecting $325 million in income to Can-Fite over the next 10 years.

What was a recent clinical milestone for Can-Fite BioPharma?

In November 2024, Can-Fite BioPharma achieved a milestone with the first patient dosing in its Pancreatic Cancer Phase IIa Clinical Trial, marking progress in its clinical development efforts.